

The Sartorius Stedim Biotech Group's half-year financial report from January to June 2011 is now available at www.sartorius-stedim.com.

It contains the following information:

- Business development for the first six months and the 2011 forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2011

Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques
B.P. 1051
13781 Aubagne - France

Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com

Aubagne | Goettingen,
August 5, 2011

A Profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions".

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs nearly 2,600 people, and in 2010 earned sales revenue of 432.9 million euros

Contact Investor Relations:

Henriette Meyer

Phone: +49.(0)551.308.3232; Fax: +49.(0)551.308.3153;

E-mail: henriette.meyer@sartorius.com; www.sartorius-stedim.com